Last 44 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.62 | — | — | — | — | — | — | — | — | — | — | — | 14.23 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 191.85 | 105.61 | 129.26 | 783.46 | 1364.49 | 1664.09 | 1186.96 | 845.23 | 24.03 | 1662.93 | 2217.88 | 2765.44 | 6.36 | — | 15.86 | 8.90 | 132682.46 | 13560.39 | 7453.30 | 6797.00 | 112.58 |
| — | -93.7% | -89.1% | -7.3% | +5578.8% | +0.1% | -46.5% | -69.4% | +277.6% | — | +13886.1% | +30984.9% | -100.0% | — | -99.8% | -99.9% | +117759.4% | +109.0% | +205964.3% | -39.9% | -98.4% | |
| P/B Ratio | 2.34 | 3.25 | 3.01 | 2.52 | 2.45 | 3.09 | 2.48 | 1.60 | 1.74 | 2.06 | 2.32 | 2.68 | 2.70 | 2.09 | 2.44 | 1.92 | 1.70 | 2.61 | 2.25 | 2.16 | 2.42 |
| — | +5.1% | +21.8% | +57.5% | +40.9% | +49.6% | +6.9% | -40.2% | -35.6% | -1.0% | -5.3% | +39.4% | +59.3% | -20.0% | +8.5% | -11.0% | -29.9% | -23.2% | -55.0% | -57.4% | -62.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 12.78 | — | — | — | 154.99 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | -91.8% | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 16.58 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | 17.75 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -6537.0% | -225.9% | -337.8% | -3346.4% | -6770.8% | -7177.1% | -5477.7% | -6548.4% | 100.0% | -2550.0% | -10920.5% | -10177.6% | 90.0% | — | 36.2% | 57.8% | -113616.7% | -41239.4% | -21369.6% | -17116.9% | -946.0% |
| — | +96.9% | +93.8% | +48.9% | -6870.8% | -181.5% | +49.8% | +35.7% | +11.1% | — | -30238.6% | -17705.8% | +100.1% | — | +100.2% | +100.3% | -11910.7% | -513.0% | -22129.0% | -75.1% | +95.7% | |
| Operating Margin | -16191.4% | -1026.5% | -1127.6% | -8933.3% | -17912.5% | -14854.8% | -14918.3% | -17158.8% | -184.5% | -18294.0% | -29257.3% | -27894.2% | 34.8% | — | -136.0% | -64.5% | -2192350.0% | -194029.8% | -115987.3% | -98860.7% | -1129.5% |
| — | +93.1% | +92.4% | +47.9% | -9606.7% | +18.8% | +49.0% | +38.5% | -630.4% | — | -21407.5% | -43155.6% | +100.0% | — | +99.9% | +99.9% | -193994.1% | -395.4% | -137012.7% | -74.3% | +96.1% | |
| Net Margin | -16569.8% | -879.6% | -895.3% | -8431.5% | -15117.2% | -11973.1% | -23379.9% | -15722.1% | -106.6% | -14276.1% | -24450.3% | -23133.1% | 44.7% | — | -111.1% | -53.1% | -1842916.7% | -185690.4% | -117616.5% | -100683.7% | -1095.0% |
| — | +92.7% | +96.2% | +46.4% | -14080.9% | +16.1% | +4.4% | +32.0% | -338.6% | — | -21916.0% | -43494.0% | +100.0% | — | +99.9% | +99.9% | -168198.2% | -380.5% | -139556.1% | -79.7% | +96.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -6.6% | -5.1% | -6.6% | -6.8% | -5.9% | -11.8% | -7.2% | -1.9% | -4.4% | -6.2% | -5.9% | 4.9% | -6.3% | -4.2% | -2.8% | -5.8% | -8.6% | -8.6% | -7.7% | -5.8% |
| — | -11.9% | +56.5% | +9.0% | -253.2% | -33.9% | -89.4% | -23.0% | -138.9% | +30.7% | -46.8% | -106.6% | +185.7% | +26.7% | +50.6% | +63.1% | -0.4% | -73.7% | -124.9% | -18.3% | +19.2% | |
| ROA | -25.8% | -4.3% | -3.4% | -4.9% | -5.8% | -5.0% | -9.9% | -6.2% | -1.7% | -3.7% | -5.3% | -5.0% | 4.1% | -5.2% | -3.5% | -2.4% | -4.8% | -7.2% | -7.3% | -6.7% | -5.1% |
| — | +14.0% | +65.9% | +20.2% | -249.1% | -33.2% | -87.9% | -23.5% | -140.1% | +28.6% | -51.1% | -111.2% | +186.0% | +27.8% | +52.3% | +64.6% | +5.1% | -63.1% | -123.5% | -11.9% | +21.6% | |
| ROIC | -22.3% | -4.4% | -3.9% | -4.7% | -5.8% | -5.3% | -5.6% | -6.1% | -2.6% | -4.5% | -6.8% | -6.3% | 3.3% | -6.5% | -4.2% | -2.6% | -5.5% | -7.7% | -7.6% | -7.5% | -6.4% |
| — | +17.3% | +30.8% | +22.2% | -128.1% | -17.0% | +17.1% | +3.8% | -177.5% | +30.7% | -60.2% | -138.5% | +160.2% | +16.0% | +43.9% | +64.9% | +14.8% | -14.2% | -112.5% | +43.1% | +64.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.47 | 0.45 | 0.43 | 0.21 | 0.21 | 0.13 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 | 0.13 | 0.14 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.09 |
| — | +124.5% | +256.4% | +262.0% | +77.5% | +79.6% | +7.8% | +6.4% | -8.7% | -16.1% | -13.5% | -13.0% | -2.6% | +12.8% | +16.4% | +21.7% | +38.7% | +51.6% | +57.9% | +212.7% | +154.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 3.20 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.32 | 16.21 | 17.85 | 17.96 | 13.25 | 16.22 | 16.61 | 15.64 | 22.07 | 21.64 | 15.73 | 17.81 | 17.54 | 15.83 | 14.00 | 13.00 | 15.30 | 12.81 | 17.57 | 19.88 | 20.17 |
| — | -0.0% | +7.4% | +14.9% | -40.0% | -25.1% | +5.6% | -12.2% | +25.8% | +36.8% | +12.4% | +37.1% | +14.6% | +23.6% | -20.3% | -34.6% | -24.1% | -51.1% | -33.0% | -9.8% | +10.7% | |
| Quick Ratio | 13.32 | 16.21 | 17.85 | 17.96 | 13.25 | 16.22 | 16.61 | 15.64 | 22.07 | 21.64 | 15.73 | 17.81 | 17.54 | 15.83 | 14.00 | 13.00 | 15.30 | 12.81 | 17.57 | 19.88 | 20.17 |
| — | -0.0% | +7.4% | +14.9% | -40.0% | -25.1% | +5.6% | -12.2% | +25.8% | +36.8% | +12.4% | +37.1% | +14.6% | +23.6% | -20.3% | -34.6% | -24.1% | -51.1% | -33.0% | -9.8% | +10.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRSP stock.
CRISPR Therapeutics AG's current P/E is -10.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CRISPR Therapeutics AG's current operating margin is -16191.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CRISPR Therapeutics AG's business trajectory between earnings reports.